Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Rocket Pharmaceuticals (RCKT)  
$21.98 0.12 (0.54%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 92,610,000
Market Cap: 2.04(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $15.07 - $31.94
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,355,932
Total Buy Value $0 $0 $0 $19,999,997
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 418,173 438,811 467,219 487,632
Total Sell Value $11,574,225 $12,042,227 $12,602,151 $12,990,263
Total People Sold 7 7 7 8
Total Sell Transactions 12 14 24 29
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 135
  Page 1 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Militello John See Remarks   •       •      –    2024-04-22 4 S $22.87 $19,051 D/D (833) 54,406 7%     
   Southwell David P   •       •      –    2024-04-15 4 S $24.05 $240,520 D/D (10,000) 114,784 8%     
   Southwell David P   •       •      –    2024-04-15 4 OE $4.34 $128,627 D/D 29,624 124,784     -
   Southwell David P   •       •      –    2024-04-12 4 S $24.22 $1,705,265 D/D (70,000) 95,160 9%     
   Southwell David P   •       •      –    2024-04-12 4 OE $4.34 $303,940 D/D 70,000 165,160     -
   White Mark Andrew See Remarks   •       •      –    2024-04-08 4 S $24.64 $308,763 D/D (12,532) 75,226 9%     
   Ondrey Aaron Chief Financial Officer   •       •      –    2024-04-01 4 A $0.00 $0 D/D 46,781 46,781     -
   Schwartz Jonathan David See Remarks   •       –      –    2024-03-25 3 IO $0.00 $0 D/D 0 172,413 -18%     
   Militello John See Remarks   •       •      –    2024-03-21 4 S $28.10 $69,979 D/D (2,490) 55,239 20%     
   Makker Gotham   •       •      –    2024-03-21 4 S $28.43 $7,790,943 I/I (274,000) 365,912 20%     
   Militello John See Remarks   •       •      –    2024-02-29 4 S $29.85 $298,450 D/D (10,000) 21,517 25%     
   Militello John See Remarks   •       •      –    2024-02-29 4 OE $12.55 $125,500 D/D 10,000 31,517     -
   Wilson Martin General Counsel   •       •      –    2024-02-29 4 S $29.33 $120,257 D/D (4,100) 18,680 25%     
   Patel Kinnari See Remarks   •       •      –    2024-02-16 4 A $0.00 $0 D/D 33,288 271,634     -
   Patel Kinnari See Remarks   •       •      –    2024-02-16 4 S $29.84 $212,805 D/D (7,132) 238,346 26%     
   Shah Gaurav CEO   •       •      –    2024-02-16 4 A $0.00 $0 D/D 66,577 621,339     -
   Shah Gaurav CEO   •       •      –    2024-02-16 4 S $29.84 $604,876 D/D (20,272) 554,762 26%     
   Militello John See Remarks   •       •      –    2024-02-16 4 A $0.00 $0 D/D 8,322 21,517     -
   Militello John See Remarks   •       •      –    2024-02-16 4 S $29.84 $96,615 D/D (3,238) 13,195 26%     
   Wilson Martin General Counsel   •       •      –    2024-02-16 4 A $0.00 $0 D/D 16,644 22,780     -
   Wilson Martin General Counsel   •       •      –    2024-02-16 4 S $29.84 $106,701 D/D (3,576) 6,136 26%     
   White Mark Andrew Chief Medical Officer   •       •      –    2024-02-16 4 A $0.00 $0 D/D 11,096 87,758     -
   Militello John See Remarks   •       •      –    2024-02-14 4 OE $0.00 $0 D/D 6,274 16,433     -
   Patel Kinnari See Remarks   •       •      –    2024-02-14 4 OE $0.00 $0 D/D 26,189 245,478     -
   Wilson Martin General Counsel   •       •      –    2024-02-14 4 OE $0.00 $0 D/D 9,712 9,712     -
  135 Records found
  1  2  3  4  5  6   
  Page 1 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us